Loading...
XASX
UBI
Market cap2mUSD
Aug 19, Last price  
0.01AUD
Name

Universal Biosensors Inc

Chart & Performance

D1W1MN
XASX:UBI chart
P/E
P/S
0.66
EPS
Div Yield, %
Shrs. gr., 5y
8.78%
Rev. gr., 5y
-1.85%
Revenues
6m
-5.28%
2,654,2801,293,5894,557,25422,042,57018,180,03614,726,89529,646,44315,089,6729,529,68416,774,97818,830,81725,191,28069,456,9146,897,1993,202,6095,777,7514,524,9626,632,8386,282,738
Net income
-14m
L+111.22%
-2,944,9750-11,995,8861,430,463-6,610,525-14,692,117-9,131,222-11,633,807-9,316,127-6,576,4161,250,276-764,71737,564,356-4,846,285-7,666,960-10,301,779-26,854,552-6,741,564-14,239,743
CFO
-12m
L-15.86%
00-7,140,3865,867,156-6,414,248-7,159,118-3,300,757-16,628,576-5,413,8691,829,5197,048,6708,689,7151,764,43733,239,631-8,291,139-9,896,620-14,702,153-14,619,044-12,300,225

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company primarily in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips; and distributes Siemens' Xprecia Stride Coagulation Analyzer, a test used to monitor the effect of the anticoagulant therapy warfarin. The company also manufactures and distributes Sentia SO2 test strips; and distributes Sentia Analyzer for the use in measurement of free SO2 levels in post-fermentation wine. In addition, it offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a biosensor strip and a meter to be used for the detection and monitoring of diabetes in animals. Universal Biosensors, Inc. was incorporated in 2001 and is headquartered in Rowville, Australia.
IPO date
Dec 13, 2006
Employees
83
Domiciled in
AU
Incorporated in
US

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT